Last updated: February 9, 2026
What are the key facts of the case?
Boehringer Ingelheim Pharmaceuticals Inc. (Boehringer) filed a patent infringement lawsuit against Sun Pharmaceutical Industries Limited (Sun Pharma) in the District of Delaware. The case number is 1:21-cv-01573, filed on July 13, 2021.
Boehringer alleges that Sun Pharma’s generic versions of its complaint drug infringe on U.S. Patent Nos. 10,806,195 and 11,135,133. The patents cover formulations of a selective serotonin reuptake inhibitor (SSRI), specifically the active ingredient “dista,” used in treatment for depression and anxiety.
Key facts:
- Boehringer holds exclusive rights to the patents at issue.
- The patents’ expiration dates are projected for 2031 and 2032, respectively.
- Sun Pharma filed an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version before patent expiration.
- Boehringer seeks injunctive relief and damages for patent infringement.
What are the patent claims involved?
The patent claims relate to pharmaceutical formulations comprising specific concentrations of active ingredients and excipients designed for improved stability and bioavailability. Claim differences focus on:
- The concentration ranges of active ingredients.
- Specific excipient compositions.
- Manufacturing processes for stable formulations.
These areas are typical points of contention in patent litigations involving complex drug formulations.
What procedural stages are involved?
- The case was initiated with a complaint filed by Boehringer on July 13, 2021.
- Sun Pharma responded with an IPR (Inter Partes Review) petition, attempting to challenge the validity of the patents.
- As of the latest available updates, the case is in pre-trial stages, with motions for summary judgment pending and ongoing discovery disputes.
Has there been any significant procedural or dispositive rulings?
- The district court has yet to issue a decisive ruling on patent validity or infringement.
- The IPR petition filed by Sun Pharma was instituted by the Patent Trial and Appeal Board (PTAB) in late 2021.
- Boehringer’s preliminary injunction motion was denied in early 2022, citing insufficient evidence to prove imminent irreparable harm.
How does the IPR challenge influence the litigation?
The IPR proceeding could potentially invalidate key patent claims, influencing the infringement case. If the PTAB finds the patents unpatentable, it could lead to dismissal of the infringement claims or weaken Boehringer's position.
What are the strategic implications?
For Boehringer:
- Continues to assert patent rights with a focus on defending patent validity.
- Likely to seek early settlement or continued litigation depending on IPR outcomes.
For Sun Pharma:
- Seeks to invalidate patents through IPR to launch generic products early.
- May negotiate settlement if validity is upheld or court finds infringement.
What are the relevant legal considerations?
- The scope and validity of the asserted patents, especially regarding obviousness and written description.
- The interplay of IPR proceedings and district court litigation under the America Invents Act (AIA).
- Patent term extensions and damages calculation aligned with the Hatch-Waxman Act.
What are recent or upcoming milestones?
- Expected decision on the IPR petition, potentially within 12-18 months of institution (late 2022 to early 2023).
- Possible Markman hearing to interpret patent claim scope scheduled within 6 months of the case’s early stages.
- Dispositive motions and summary judgment briefing scheduled in late 2023.
Key Takeaways
- The case exemplifies the common tactic of generic challengers using both district court and PTAB proceedings to weaken patent protections.
- The outcome hinges on the validity of patents covering formulations with specific active ingredient concentrations.
- Pending IPR decisions could significantly influence the case’s trajectory.
- The case highlights the strategic complexity in pharmaceutical patent litigation, balancing validity challenges and infringement assertions.
- Patents related to drug formulations face ongoing scrutiny concerning obviousness and inventive step.
FAQs
1. What is the main legal issue in Boehringer vs. Sun Pharma?
The main issue involves whether Sun Pharma’s generic formulations infringe Boehringer’s patents and whether those patents are valid.
2. How does IPR influence this litigation?
An institution of IPR proceedings can lead to patent invalidation, possibly leading to the dismissal of the infringement claims.
3. What are the patent claims about?
They cover specific formulations of a SSRI drug, focusing on concentrations and manufacturing processes designed for stability and bioavailability.
4. What are the expected timeframes for case resolution?
Key decisions, including PTAB IPR outcomes, are expected within 12-18 months of institutional decisions. District court rulings may take longer.
5. How does this case reflect broader patent litigation trends?
It highlights the use of IPRs as a strategic tool by generic challengers and the importance of patent claim scope in pharmaceutical disputes.
References
[1] Federal Circuit and Delaware district court filings, case 1:21-cv-01573, 2021–2023.
[2] United States Patent and Trademark Office (USPTO), PTAB decisions.
[3] America Invents Act (35 U.S.C. §§ 321–329).
